Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.8 (
FAST
)
758
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The t(8;21) translocation, found in adult acute myelogenous leukemia, results in the formation of an
AML1
/ETO chimeric transcription factor.
AML1
/ETO expression leads to alterations in hematopoietic progenitor cell differentiation, although its role in leukemic transformation is not clear. The N-terminal portion of
AML1
, which is retained in
AML1
/ETO, contains a region of homology to the
FAST
proteins, which cooperate with Smads to regulate transforming growth factor beta1 (TGF-beta1) target genes. We have demonstrated the physical association of Smad proteins with
AML1
and
AML1
/ETO by immunoprecipitation and have mapped the region of interaction to the runt homology domain in these
AML1
proteins. Using confocal microscopy, we demonstrated that
AML1
, and ETO and/or
AML1
/ETO, colocalize with Smads in the nucleus of t(8;21)-positive Kasumi-1 cells, in the presence but not the absence of TGF-beta1. Using transient transfection assays and a reporter gene construct that contains both Smad and
AML1
consensus binding sequences, we demonstrated that overexpression of AML1B cooperates with TGF-beta1 in stimulating reporter gene activity, whereas
AML1
/ETO represses basal promoter activity and blocks the response to TGF-beta1. Considering the critical role of TGF-beta1 in the growth and differentiation of hematopoietic cells, interference with TGF-beta1 signaling by
AML1
/ETO may contribute to leukemogenesis.
...
PMID:Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. 1103 26